The STEP (Semaglutide Treatment Effect in People with obesity) trial program showed that participants using semaglutide 2.4 mg weekly achieved an average weight loss of 12-15% of their initial body weight over 68 weeks, compared to 2-3% with placebo
Who should (and should not) take semaglutide for weight loss
The defendants are urging the court to require that a gastroparesis diagnosis be based on objective, contemporaneous testing
Various methods have been proposed to enable oral delivery of protein and peptide therapeutics, including coadministration of compounds that alter the physiology of the GI tract, drug modifications, and delivery of the drug via a carrier, which was reviewed by Wagner et al
Retatrutide is a synthetic research peptide currently being studied for its multi-receptor activity in controlled laboratory environments
How does drinking alcohol affect a GLP-1 medication